Skip to main content
Top
Published in: BMC Gastroenterology 1/2017

Open Access 01-12-2017 | Research article

Noninvasive assessment of liver steatosis in children: the clinical value of controlled attenuation parameter

Authors: Giovanna Ferraioli, Valeria Calcaterra, Raffaella Lissandrin, Marinella Guazzotti, Laura Maiocchi, Carmine Tinelli, Annalisa De Silvestri, Corrado Regalbuto, Gloria Pelizzo, Daniela Larizza, Carlo Filice

Published in: BMC Gastroenterology | Issue 1/2017

Login to get access

Abstract

Background

To assess the clinical validity of controlled attenuation parameter (CAP) in the diagnosis of hepatic steatosis in a series of overweight or obese children by using the imperfect gold standard methodology.

Methods

Consecutive children referred to our institution for auxological evaluation or obesity or minor elective surgery were prospectively enrolled. Anthropometric and biochemical parameters were recorded. Ultrasound (US) assessment of steatosis was carried out using ultrasound systems. CAP was obtained with the FibroScan 502 Touch device (Echosens, Paris, France). Pearson’s or Spearman’s rank correlation coefficient were used to test the association between two study variables. Optimal cutoff of CAP for detecting steatosis was 249 dB/m. The diagnostic performance of dichotomized CAP, US, body mass indexes (BMI), fatty liver index (FLI) and hepatic steatosis index (HSI) was analyzed using the imperfect gold standard methodology.

Results

Three hundred five pediatric patients were enrolled. The data of both US and CAP were available for 289 children. Steatosis was detected in 50/289 (17.3%) children by US and in 77/289 (26.6%) by CAP. A moderate to good correlation was detected between CAP and BMI (r = 0.53), FLI (r = 0.55) and HSI (r = 0.56). In obese children a moderate to good correlation between CAP and insulin levels (r = 0.54) and HOMA-IR (r = 0.54) was also found. Dichotomized CAP showed a performance of 0.70 (sensitivity, 0.72 [0.64–0.79]; specificity, 0.98 [0.97–0.98], which was better than that of US (performance, 0.37; sensitivity, 0.46 [0.42–0.50]; specificity, 0.91 [0.89–0.92]), BMI (performance, 0.22; sensitivity, 0.75 [0.73–0.77]; specificity, 0.57 [0.55–0.60]) and FLI or HSI.

Conclusions

For the evaluation of liver steatosis in children CAP performs better than US, which is the most widely used imaging technique for screening patients with a suspicion of liver steatosis. A cutoff value of CAP of 249 dB/m rules in liver steatosis with a very high specificity.
Literature
1.
6.
go back to reference Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36(11):1825–35. doi:10.1016/j.ultrasmedbio.2010.07.005.CrossRefPubMed Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36(11):1825–35. doi:10.​1016/​j.​ultrasmedbio.​2010.​07.​005.CrossRefPubMed
8.
11.
go back to reference Kim SH, Lee JM, Kim JH, Kim KG, Han JK, Lee KH, et al. Appropriateness of a donor liver with respect to macrosteatosis: application of artificial neural networks to US images-initial experience. Radiology. 2005;234(3):793–803. doi:10.1148/radiol.2343040142.CrossRefPubMed Kim SH, Lee JM, Kim JH, Kim KG, Han JK, Lee KH, et al. Appropriateness of a donor liver with respect to macrosteatosis: application of artificial neural networks to US images-initial experience. Radiology. 2005;234(3):793–803. doi:10.​1148/​radiol.​2343040142.CrossRefPubMed
12.
go back to reference Boursier J, Zarski JP, de Ledinghen V, Rousselet MC, Sturm N, Lebail B, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology. 2013;57(3):1182–91. doi:10.1002/hep.25993.CrossRefPubMed Boursier J, Zarski JP, de Ledinghen V, Rousselet MC, Sturm N, Lebail B, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology. 2013;57(3):1182–91. doi:10.​1002/​hep.​25993.CrossRefPubMed
13.
go back to reference Colton T, editor. Statistics in medicine. Boston: Little, Brown and Company; 1974. Colton T, editor. Statistics in medicine. Boston: Little, Brown and Company; 1974.
14.
go back to reference Ferraioli G, Tinelli C, De Silvestri A, Lissandrin R, Above E, Dellafiore C, et al. The clinical value of controlled attenuation parameter for the noninvasive assessment of liver steatosis. Liver Int. 2016;36(12):1860–6. doi:10.1111/liv.13207.CrossRefPubMed Ferraioli G, Tinelli C, De Silvestri A, Lissandrin R, Above E, Dellafiore C, et al. The clinical value of controlled attenuation parameter for the noninvasive assessment of liver steatosis. Liver Int. 2016;36(12):1860–6. doi:10.​1111/​liv.​13207.CrossRefPubMed
20.
go back to reference Koot BG, van der Baan-Slootweg OH, Bohte AE, Nederveen AJ, van Werven JR, Tamminga-Smeulders CL, et al. Accuracy of prediction scores and novel biomarkers for predicting nonalcoholic fatty liver disease in obese children. Obesity (Silver Spring). 2013;21(3):583–90. doi:10.1002/oby.20173.CrossRef Koot BG, van der Baan-Slootweg OH, Bohte AE, Nederveen AJ, van Werven JR, Tamminga-Smeulders CL, et al. Accuracy of prediction scores and novel biomarkers for predicting nonalcoholic fatty liver disease in obese children. Obesity (Silver Spring). 2013;21(3):583–90. doi:10.​1002/​oby.​20173.CrossRef
21.
go back to reference Rutjes AW, Reitsma JB, Coomarasamy A, Khan KS, Bossuyt PM. Evaluation of diagnostic tests when there is no gold standard. A review of methods. Health Technol Assess. 2007;11(50):iii. doi:10.3310/hta11500. ix-51.CrossRefPubMed Rutjes AW, Reitsma JB, Coomarasamy A, Khan KS, Bossuyt PM. Evaluation of diagnostic tests when there is no gold standard. A review of methods. Health Technol Assess. 2007;11(50):iii. doi:10.​3310/​hta11500. ix-51.CrossRefPubMed
Metadata
Title
Noninvasive assessment of liver steatosis in children: the clinical value of controlled attenuation parameter
Authors
Giovanna Ferraioli
Valeria Calcaterra
Raffaella Lissandrin
Marinella Guazzotti
Laura Maiocchi
Carmine Tinelli
Annalisa De Silvestri
Corrado Regalbuto
Gloria Pelizzo
Daniela Larizza
Carlo Filice
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2017
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-017-0617-6

Other articles of this Issue 1/2017

BMC Gastroenterology 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine